Partnering is a core feature of how Roche delivers impact in the communities where we live and work. We recognize that innovation is taking place all around us and we welcome opportunities to work together toward the same goal, better care for more patients faster.

As a healthcare company Roche recognizes the important role we play in helping to shape and improve our local healthcare system and supporting the full patient journey. With this commitment, Roche prefers to invest in programs and initiatives that have a direct impact on patient care and benefit research in areas of high unmet medical need.

Support can take many forms including medical and education grants, donations and sponsorships with a focus on Roche’s therapeutic areas of business. Roche is also interested in projects that support improvement to the healthcare and patient ecosystem as a whole; this includes an increased investment in personalized healthcare and real-world evidence.

For more information about our therapeutic areas, funding policies, or to start a funding request please visit the

Roche further supports initiatives that involve clinical and pre-clinical activities that may or may not involve Roche’s therapeutic molecules. Requests for support of these activities are processed differently than our medical and education grants, sponsorships and donations as detailed above. Please select the program below to learn how to request support.

Roche and Genentech are proud to support basic research and pre-clinical projects that advance our knowledge and understanding of disease, treatment and mechanisms of action by supplying academic and research institutions throughout the world with key reagents and mice for basic research purposes.about Genentech’s outgoing material transfer agreement (MTA) program.

Roche is invested in the advancement of scientific knowledge and answering important medical and scientific questions regarding Roche’s products and therapeutic areas of interest. Our investigator-initiated studies (IIS) support clinical interventional studies (phase I to IV) involving marketed Roche drugs or those still in development as well as non-interventional studies such as observational or real-world evidence.Roche’s IIS programs are improving patient care, and sparking new ideas for disease-related research aimed at creating improved treatment for patients.

Roche Diagnostics is the world leader in in vitro diagnostics, offering a wide range of analytical and diagnostics systems and reagents, as well as providing innovative diabetes management solutions. 

To request sponsorship/donation support from Roche Diagnostics Canada or Roche Diabetes Care Canada please visit the

Roche is working with Canadian institutions and companies to drive exceptional science and pioneer medical breakthroughs, helping Canada to be a world leader in scientific discovery.

Together we can help to deliver maximum impact to health systems and, ultimately, to patients.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

You are now leaving the website of Hoffmann-La Roche Ltd. ("Roche Canada"). Links to all external sites are provided as a resource to our visitors. Roche Canada assumes no responsibility for the content of these sites. Roche Canada has no control over these sites and the opinions, claims or comments contained in these sites should not be attributed to Roche Canada, unless otherwise specified.